Novavax begins early-stage trial for combined influenza/COVID-19 vaccine

Vaccine developer Novavax Inc said on Wednesday it has initiated an early-stage study to test its combined flu and COVID-19 vaccine.

The trial, to be conducted in Australia, will enroll 640 healthy adults between the ages of 50 and 70 years and who have either been previously infected with the coronavirus or given an authorized COVID-19 vaccine at least eight weeks prior to the study. Participants will receive a combination of the company's COVID-19 vaccine candidate, NVX-CoV2373, and its Influenza shot NanoFlu along with an adjuvant or vaccine booster.